La liste ci-dessous contient des informations sur les essais cliniques financés par Ipsen.
Seules les études interventionnelles qui ont débuté au cours des 20 dernières années et se sont achevées au cours des 2 dernières années seront affichées.
Les résultats de l’étude seront disponibles sur ClinicalTrials.gov à partir de 12 mois après la fin de l’étude.
Last Data Refreshed @ 11-Apr-2025 06:08:06 UTC
Filtres
Country
Showing : 1 – 5 de 5 clinical trials
Precocious Puberty
Decapeptyl
France
Completed
Efficacy and Safety Study of Pamoate of Triptorelin in Children With Precocious Puberty
The purpose of the study
is to assess the efficacy
of triptorelin 11.25 mg pamoate in the delay of premature onset of puberty in girls less than 9 years and boys less than 10 years. This is measured by assessing the proportion of children who have a suppressed Luteinizing Hormone (LH) response to Gonadotropin Releasing Hormone (GnRH) test performed 3 months after injection with triptorelin 11.25 mg.
Precocious Puberty
Decapeptyl
France
Completed
Effects of Triptorelin Pamoate in Children With Precocious Puberty – Follow up Study
The purpose of the protocol is to assess the efficacy of triptorelin 11.25 mg with respect to the proportion of children who maintain a regression or
stabilisation of sexual maturity until the end of the study.
Endocrine Tumors
Somatuline
United States of America (the)
United Kingdom of Great Britain and Northern Ireland (the)
Spain
Slovakia
Sweden
Poland
Belgium
France
Czechia
Denmark
Germany
India
Italy
Austria
Completed
Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours
The study will compare the difference between lanreotide Autogel and placebo on progression free survival in patients who have an endocrine tumour in the pancreas or intestines.
Acromegaly
Somatuline
Italy
Greece
Germany
Denmark
Czechia
France
Netherlands (Kingdom of the)
Sweden
Spain
United Kingdom of Great Britain and Northern Ireland (the)
Completed
Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients
The main aim of this study is to assess the efficacy of the co-administration of lanreotide Autogel 120 mg (administered via deep sub-cutaneous injections every 28 days) and pegvisomant (administered at 40 to 120 mg per week via sub-cutaneous injection given once or twice a week) on IGF-1 levels over 28 weeks in acromegalic patients. The primary endpoint will be the percentage of acromegalic patients with normalised (age and sex adjusted) IGF-1 level at the end of the co-treatment period.
Prostate Cancer
Decapeptyl
France
Lithuania
Latvia
Belgium
Poland
Spain
United Kingdom of Great Britain and Northern Ireland (the)
Ukraine
Terminated
Study to Evaluate a Subcutaneous Four Months Sustained-Release Formulation of Triptorelin in Patients With Prostate Cancer
To identify the proportion of patients remaining medically castrated (testosterone level < 50 ng/dL) on Day 240 following two administrations of a 4-month sustained-release (SR) formulation of triptorelin.